enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Anti-amyloid drugs - Wikipedia

   en.wikipedia.org/wiki/Anti-amyloid_drugs

   Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...

3. Eplontersen - Wikipedia

   en.wikipedia.org/wiki/Eplontersen

   Eplontersen, sold under the brand name Wainua, is a medication used for the treatment of transthyretin-mediated amyloidosis. [3] It is a transthyretin-directed antisense oligonucleotide. [ 3 ] It was developed to treat hereditary transthyretin amyloidosis by Ionis Pharmaceuticals and AstraZeneca .

4. Aducanumab - Wikipedia

   en.wikipedia.org/wiki/Aducanumab

   Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

5. New test may tell who is prone to side effects from Alzheimer ...

   www.aol.com/test-may-tell-prone-side-153000197.html

   Since July 2023, three anti-amyloid medications have been FDA-approved for the treatment of Alzheimer’s disease with more in development. A potential and serious side effect of anti-amyloid ...

6. U.S. approves Alzheimer's drug that modestly slows disease - AOL

   www.aol.com/news/alzheimers-drug-modestly-slows...

   A string of other amyloid-targeting drugs have failed and many researchers now think combination treatments will be needed. Aduhelm, the similar drug, was marred by controversy over its effectiveness.

7. Eli Lilly Alzheimer's drug approved by US FDA - AOL

   www.aol.com/news/us-fda-approves-lillys...

   A key differentiating factor for donanemab is the drug's finite dosing, which allows patients to stop taking the treatment once brain scans no longer show amyloid plaques. Lilly priced its drug at ...